Protagenic Therapeutics Forum: Community User: Rentnergang

Protagenic Therapeutics (NASDAQ:PTIX) reported positive topline safety results from its Phase 1 multiple-dose study of PT00114 in healthy volunteers on December 9, 2025. All planned cohorts completed dosing and PT00114 was reported as well tolerated across all dose ranges. No serious adverse events were observed; reported adverse events were consistent with a peptide injectable, including expected injection-site reactions. Several participants reported an improved sense of well-being (anecdotal). The company is finalizing full Phase 1 analyses and expects to initiate a Phase 2 study in early 2026 to evaluate PT00114 in chronic stress-related psychiatric disorders.

Was passiert hier grade 😳

😊

Was steht an,finde nix....

☕️